OPK-88006 vs Zabopegdutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

MASH / NASH

Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline

OPK-88006

Developed by OPKO Health

Phase 1/2 in MASH / NASH
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07512427 (registry estimate)

No aligned efficacy figure on record for this race.

Zabopegdutide

Developed by D&D Pharmatech and partners

Phase 2 in MASH / NASHpeptide
Partial signal

NCT06410924 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.

Reported efficacy

Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFF (12 weeks): Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. (met)

Result source: NCT06410924

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOPK-88006Zabopegdutide
MASH resolution without fibrosis worsening—Not reported—Not reported
Fibrosis stage, change—Not reported—Not reported
Liver fat (MRI-PDFF), change—Not reported—Not reported
ALT, change—Not reported—Not reported

MASH resolution without fibrosis worsening

OPK-88006
—Not reported
Zabopegdutide
—Not reported

Fibrosis stage, change

OPK-88006
—Not reported
Zabopegdutide
—Not reported

Liver fat (MRI-PDFF), change

OPK-88006
—Not reported
Zabopegdutide
—Not reported

ALT, change

OPK-88006
—Not reported
Zabopegdutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

OPK-88006: no structured comparison results are available for MASH / NASH.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zabopegdutide

MRI-PDFF ≥30% 75.8% vs 11.8% placebo @ 12wk
responder rate · % of participants
NCT06410924 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: OPK-88006's landscape · Zabopegdutide's landscape